Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.
James L AlexanderHajir IbraheimBhavisha ShethJessica LittleMuhammad Saheb KhanCamellia RichardsNikki HunterDharmisha ChauhanRaguprakash RatnakumaranKathleen McHughDavid James PinatoPaul NathanJulia ChoyShanthini M CruszAndrew FurnessSamra TurajlicLisa PickeringJames LarkinJulian P TeareSophie PapaAlly SpeightAnand SharmaNicholas PowellPublished in: Journal for immunotherapy of cancer (2022)
This is the largest study to date reporting outcomes of IFX therapy in patients with corticosteroid-refractory CPI-induced enterocolitis. Using predefined robust endpoints, we have demonstrated that fewer than half of patients achieved CFCR. Our data also indicate that cancer outcomes may be better in patients developing prolonged and severe inflammatory side effects of CPI therapy.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- oxidative stress
- type diabetes
- high glucose
- squamous cell carcinoma
- machine learning
- diabetic rats
- early onset
- electronic health record
- metabolic syndrome
- papillary thyroid
- preterm infants
- deep learning
- weight loss
- artificial intelligence
- replacement therapy